Dr. Dannenberg on Inflammation and Increased Breast Cancer Risk

Andrew Dannenberg, MD
Published: Thursday, May 07, 2015



Andrew Dannenberg, MD, professor of Medicine, Weill Cornell Medical College, discusses the association between breast inflammation and breast cancer.  In a study looking at women with metastatic breast cancer, long-term distant recurrence-free survival was reduced in those who had white adipose or occult inflammation compared to those who did not.  

Although white adipose inflammation of the breast has previously been associated with elevated body mass index (BMI), Dannenberg reported that approximately one-third of normal BMI women have breast inflammation. This inflammation is believed to contribute to insulin resistance, which is associated with an increased risk of breast cancer among those with a normal BMI.  

This means that many women at a healthy weight may have an unrecognized risk factor for breast cancer.



Andrew Dannenberg, MD, professor of Medicine, Weill Cornell Medical College, discusses the association between breast inflammation and breast cancer.  In a study looking at women with metastatic breast cancer, long-term distant recurrence-free survival was reduced in those who had white adipose or occult inflammation compared to those who did not.  

Although white adipose inflammation of the breast has previously been associated with elevated body mass index (BMI), Dannenberg reported that approximately one-third of normal BMI women have breast inflammation. This inflammation is believed to contribute to insulin resistance, which is associated with an increased risk of breast cancer among those with a normal BMI.  

This means that many women at a healthy weight may have an unrecognized risk factor for breast cancer.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x